Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2006-05-19
2011-12-13
Bausch, Sarae (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C436S063000, C436S064000
Reexamination Certificate
active
08076065
ABSTRACT:
The present invention provides methods for the assessment of risk of developing lung cancer in smokers and non-smokers using analysis of genetic polymorphisms. The present invention also relates to the use of genetic polymorphisms in assessing a subject's risk of developing lung cancer. Nucleotide probes and primers, kits, and microarrays suitable for such assessment are also provided.
REFERENCES:
patent: 4829052 (1989-05-01), Glover et al.
patent: 5455262 (1995-10-01), Schwartz et al.
patent: 5674754 (1997-10-01), Ahrens et al.
patent: 5773430 (1998-06-01), Simon et al.
patent: 5827662 (1998-10-01), Rubin
patent: 5837492 (1998-11-01), Tavtigian
patent: 5840698 (1998-11-01), Campbell et al.
patent: 5844108 (1998-12-01), Meyer
patent: 5851983 (1998-12-01), Sugiyama et al.
patent: 5932579 (1999-08-01), Campbell et al.
patent: 5935852 (1999-08-01), Follettie
patent: 6022893 (2000-02-01), Sakaki et al.
patent: 6033857 (2000-03-01), Tavtigian
patent: 6057292 (2000-05-01), Cunningham et al.
patent: 6057297 (2000-05-01), Politi et al.
patent: 6060283 (2000-05-01), Okura
patent: 6117869 (2000-09-01), Picard et al.
patent: 6171798 (2001-01-01), Levine
patent: 6183963 (2001-02-01), Sinnett
patent: 6184022 (2001-02-01), Seiki et al.
patent: 6187587 (2001-02-01), Popoff et al.
patent: 6211209 (2001-04-01), Baragi et al.
patent: 6268142 (2001-07-01), Duff
patent: 6346385 (2002-02-01), Eguchi et al.
patent: 6387615 (2002-05-01), Cookson et al.
patent: 6610510 (2003-08-01), Valenzuela
patent: 6673549 (2004-01-01), Furness
patent: 6677442 (2004-01-01), Wang
patent: 6706478 (2004-03-01), Duff
patent: 6716581 (2004-04-01), Lenz
patent: 7054758 (2006-05-01), Gill-Garrison et al.
patent: 2002/0197646 (2002-12-01), Nogee et al.
patent: 2004/0106120 (2004-06-01), Tazi-Ahnini et al.
patent: 2004/0152124 (2004-08-01), Duff
patent: 2004/0219548 (2004-11-01), Young
patent: 2004/0241714 (2004-12-01), Branch
patent: 2005/0064454 (2005-03-01), Young
patent: 2005/0196754 (2005-09-01), Drmanac
patent: 2005/0272054 (2005-12-01), Cargill
patent: 2005/0282198 (2005-12-01), Duff
patent: 2006/0122373 (2006-06-01), Mccarthy
patent: 2006/0269946 (2006-11-01), Young
patent: 2006/0275808 (2006-12-01), Young
patent: 2006/0281114 (2006-12-01), Young
patent: 0 854 191 (1998-07-01), None
patent: 1 043 406 (2006-06-01), None
patent: 2005328707 (2005-12-01), None
patent: 543520 (2005-11-01), None
patent: 543985 (2005-12-01), None
patent: 544034 (2005-12-01), None
patent: 547579 (2006-05-01), None
patent: WO 01/53537 (2001-07-01), None
patent: WO 02/097127 (2002-12-01), None
patent: WO 02/099134 (2002-12-01), None
patent: WO 2006121351 (2006-11-01), None
patent: WO2006123943 (2006-11-01), None
patent: WO 2006123954 (2006-11-01), None
patent: WO2006123955 (2006-11-01), None
Schabath (Lung Cancer 2002 vol. 37, pp. 35-40).
Lee et al. (Carcinogenesis, 2007, vol. 28, pp. 1437-1441) and supplemental data, p. 1-6.
Campa et al. (Cancer Epidemiol. Biomarkers Prey 2005; 14 (10): 2457-8).
lonnidis (Plost Med, 2005, 2(8):e124).
Kroese et al. (Genetics in Medicine, vol. 6 (2004), p. 475-480).
Hegele et al. (Arterioscler. Thromb. Vasc. Biol. 2002, vol. 22, pp. 1058-1061).
Wall et al. Nature Review Genetics, 2003, vol. 4, pp. 587-597.
Cheon, K. T. et al. 2000. Gene polymorphisms of endothelial nitric oxide synthase and angiotensin-converting enzyme in patients with lung cancer.Lung178:351-360.
Fairchild, T. A., et al. 2001. Acidic hydrolysis as a mechanism for the cleavage of the Glu298→Asp variant of human endothelial nitric-oxide synthase.J Biol Chem276(28):26674-26679.
Slowik, A, et al. 2005. α1-Antichymotrypsin gene (serpinaA3) A/T polymorphism as a risk factor for anneurysmal subarachnoid hemorrhage.Stroke36:737-740.
U.S. Appl. No. 11/432,736, filed May 10, 2006, Young.
U.S. Appl. No. 11/432,770, filed May 2006, Young.
U.S. Appl. No. 11/438,082, filed May 19, 2006, Young.
Minematsu et al. “Genetic polymorphism in Matrix Metalloproteinase-9 and pulmonary emphysema,” Biochemical and Biophysical Research Communication vol. 289, pp. 116-119 (Nov. 2001).
Nazar-Stewart, V et al., “A population-based study of glutathione S-transferase M1, T1 and P1 genotypes and risk for lung cancer”, Lung Cancer 40 (2003) 247-258.
Nomura, A et al., “Prospective study of pulmonary function and lung cancer”, Am Rev Respir Dis 1991; 144:307-311.
Park, J A et al., “The human 8-oxoguanine DNA N-glycosylase 1 (hOGG1) DNA repair enzyme and its association with lung cancer risk”, Pharmacogenetics 14(2):103-109, Feb. 2004.
Park, J Y et al., “Polymorphism of the DNA repair gene XRCC1 and risk of primary lung cancer”, Cancer Epidemiology, Biomarkers & Prevention, vol. 11, Jan. 23-27, 2002.
Poller et al., “DNA polymorphisms of the al-antitrypsin gene region in patients with chronic obstructive pulmonary disease,” European Journal of Clinical Investigation, 20:1-7 (1990).
Popanda, O et al., “Specific combinations of DNA repair gene variants and increased risk for non-small cell lung cancer”, Carcinogenesis Advance Access, Aug. 27, 2004.
Qiuling, S et al., “Cyclin D1 gene polymorphism and susceptibility to lung cancer in a Chinese population”, Carcinogenesis, vol. 24, No. 9, pp. 1499-1503, 2003.
Ratnasinghe, D et al., “Polymorphisms of the DNA repair gene XRCC1 and lung cancer risk”, Cancer Epidemiology, Biomarkers & Prevention, vol. 10, 119-123, Feb. 2001.
Rinehart et al., “Human Alpha(1)-Proteinase Inhibitor Binds to Extracellular-Matrix In-Vitro,” American Journal of Respiratory Cell and Molecular Biology, vol. 9, No. 6, pp. 666-679 (Dec. 1993).
Sandford et al, “Mutation in the 3′ region of the α-1 antitrypsin gene and chronic obstructive pulmonary disease,” J. Med. Genet., 34:874-875 (1997).
Sandford et al., “Genetic risk factors for chronic obstructive pulmonary disease,” Eur. Respir. J., 10:1380-1391 (1997).
Schwartz, A G, “Genetic predisposition to lung cancer”, Chest, 2004; 125:86S-89S.
Shapiro, “Diverse Roles of Macrophage Matrix Metalloproteinases in Tissue Destruction and Tumor Growth,” Thromb Haemost., 82:846-849 (1999).
Skillrud, D M et al., “Higher risk of lung cancer in chronic obstructive pulmonary disease”, Annals of Internal Medicine, 1986;105:503-507.
Smith, I, “Spirometry's COPD-lung cancer connection”, The Journal for Respiratory Care Practitioners, Dec./Jan. 1996, pp. 70-71.
Sorsa et al., “Doxycycline in the Protection of Serum Alpha-1-Antitrypsin from Human Neutrophil Collagenase and Gelatinase,” Antimicrobial Agents and Chemotherapy, vol. 37, No. 3, pp. 592-594 (1993).
Spitz, M R et al., “Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients”, Cancer Research 61, 1354-1357, Feb. 15, 2001.
Syrris et al., “Transforming growth factor-β1 gene polymorphisms and coronary artery disease,” Clinical Science, 95:659-667 (1998).
Tockman, M S et al., “Airways obstruction and the risk for lung cancer”, Annals of Internal Medicine, 1987;106:512-518.
Vineis, P et al., “CYP1A T3801C polymorphism and lung cancer: a pooled analysis of 2,451 cases and 3,358 controls”, Int. J. Cancer: 104, 650-657 (2003).
Walter et al., “Environmental and genetic risk factors and gene-environment interactions in the pathogenesis of chronic lung disease,” Environmental Health Perspectives, vol. 108, Suppl. 4, pp. 733-742 (2000).
Wang, J et al., “Association of GSTM1, CYP1A1 and CYP2E1 genetic polymorphisms with susceptibility to lung adenocarcinoma: a case-control study in Chinese population”, Cancer Science, 94(5):448-52, May 2003.
Wang, L-E et al., “Fas A670G polymorphism, apoptotic capacity in lymphocyte cultures, and risk of lung cancer”, Lung Cancer (2003) 42, 1-8.
Wang, Y et al., “From genotype to phenotype: correlating XRCC1 polymorphisms with mutagen sensi
Bausch Sarae
Davis , Wright, Tremaine, LLP
Synergenz Bioscience Limited
LandOfFree
Methods and compositions for assessment of pulmonary... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for assessment of pulmonary..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for assessment of pulmonary... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4296522